Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 21 | 2024 | 1723 | 2.480 |
Why?
|
| Receptors, Estrogen | 13 | 2019 | 183 | 2.450 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 11 | 2018 | 133 | 1.940 |
Why?
|
| Receptors, Progesterone | 5 | 2021 | 92 | 1.640 |
Why?
|
| Lung Neoplasms | 11 | 2018 | 495 | 1.610 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2019 | 47 | 1.340 |
Why?
|
| Signal Transduction | 17 | 2024 | 2157 | 1.310 |
Why?
|
| Estrogen Receptor beta | 4 | 2015 | 39 | 1.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 220 | 1.210 |
Why?
|
| Cell Proliferation | 8 | 2024 | 1455 | 1.060 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2017 | 25 | 1.000 |
Why?
|
| Estrogens | 7 | 2022 | 203 | 0.910 |
Why?
|
| Honey | 1 | 2024 | 15 | 0.860 |
Why?
|
| Antineoplastic Agents | 7 | 2024 | 1019 | 0.860 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2023 | 5 | 0.810 |
Why?
|
| Cell Membrane | 5 | 2017 | 403 | 0.770 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2019 | 183 | 0.750 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2019 | 62 | 0.750 |
Why?
|
| Estrogen Receptor Modulators | 5 | 2013 | 19 | 0.750 |
Why?
|
| Aromatase | 5 | 2011 | 20 | 0.750 |
Why?
|
| Cell Line, Tumor | 14 | 2024 | 2676 | 0.660 |
Why?
|
| Mammary Glands, Human | 1 | 2021 | 40 | 0.650 |
Why?
|
| Estradiol | 6 | 2023 | 268 | 0.630 |
Why?
|
| Estrogen Antagonists | 1 | 2019 | 30 | 0.600 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 307 | 0.600 |
Why?
|
| Mice, Nude | 9 | 2024 | 408 | 0.600 |
Why?
|
| Phenylthiohydantoin | 1 | 2017 | 5 | 0.550 |
Why?
|
| Pyrazoles | 2 | 2017 | 103 | 0.550 |
Why?
|
| Apoptosis | 4 | 2024 | 1568 | 0.550 |
Why?
|
| Androgen Antagonists | 1 | 2017 | 29 | 0.540 |
Why?
|
| Triazines | 1 | 2017 | 25 | 0.540 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2017 | 28 | 0.540 |
Why?
|
| Female | 31 | 2024 | 24698 | 0.540 |
Why?
|
| Pyrroles | 1 | 2017 | 72 | 0.520 |
Why?
|
| Humans | 41 | 2024 | 43102 | 0.510 |
Why?
|
| Pyrimidines | 1 | 2017 | 139 | 0.500 |
Why?
|
| Neoplasms | 2 | 2023 | 1377 | 0.490 |
Why?
|
| Somatomedins | 1 | 2015 | 6 | 0.450 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 968 | 0.420 |
Why?
|
| Mice | 12 | 2024 | 6644 | 0.410 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 228 | 0.390 |
Why?
|
| Aromatase Inhibitors | 4 | 2007 | 19 | 0.370 |
Why?
|
| Nitriles | 2 | 2017 | 81 | 0.360 |
Why?
|
| Cell Nucleus | 3 | 2011 | 383 | 0.350 |
Why?
|
| Animals | 16 | 2024 | 16992 | 0.340 |
Why?
|
| Phosphorylation | 3 | 2024 | 986 | 0.340 |
Why?
|
| Cholestanols | 2 | 2019 | 5 | 0.340 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 347 | 0.330 |
Why?
|
| Membrane Proteins | 2 | 2017 | 561 | 0.310 |
Why?
|
| Breast | 2 | 2021 | 139 | 0.280 |
Why?
|
| Hormones | 2 | 2005 | 55 | 0.270 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2023 | 223 | 0.270 |
Why?
|
| Steroids | 2 | 2005 | 45 | 0.270 |
Why?
|
| Estrogen Receptor alpha | 3 | 2007 | 121 | 0.270 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2006 | 19 | 0.250 |
Why?
|
| Disease Progression | 2 | 2024 | 667 | 0.240 |
Why?
|
| Membrane Microdomains | 1 | 2006 | 53 | 0.240 |
Why?
|
| Growth Substances | 1 | 2005 | 16 | 0.230 |
Why?
|
| Triazoles | 1 | 2005 | 102 | 0.220 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2005 | 93 | 0.220 |
Why?
|
| Leptospermum | 1 | 2024 | 2 | 0.220 |
Why?
|
| Neovascularization, Pathologic | 2 | 2003 | 139 | 0.220 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2024 | 68 | 0.210 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 237 | 0.210 |
Why?
|
| STAT3 Transcription Factor | 1 | 2024 | 102 | 0.200 |
Why?
|
| Gene Expression | 2 | 2005 | 701 | 0.190 |
Why?
|
| Neutrophils | 1 | 2023 | 145 | 0.190 |
Why?
|
| Progesterone | 1 | 2022 | 121 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 299 | 0.180 |
Why?
|
| Anticarcinogenic Agents | 1 | 2002 | 77 | 0.180 |
Why?
|
| Cisplatin | 1 | 2002 | 98 | 0.180 |
Why?
|
| Androgens | 2 | 2022 | 106 | 0.170 |
Why?
|
| Transplantation, Heterologous | 4 | 2009 | 98 | 0.160 |
Why?
|
| Cell Survival | 3 | 2017 | 945 | 0.160 |
Why?
|
| Survival Analysis | 2 | 2018 | 368 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 27 | 0.150 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2019 | 22 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2019 | 144 | 0.140 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 53 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 694 | 0.130 |
Why?
|
| Neoplasm Transplantation | 2 | 2011 | 129 | 0.130 |
Why?
|
| Benzamides | 1 | 2017 | 81 | 0.130 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 374 | 0.130 |
Why?
|
| Cell Division | 3 | 2009 | 311 | 0.130 |
Why?
|
| Transcription, Genetic | 3 | 2011 | 592 | 0.130 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 38 | 0.120 |
Why?
|
| Warfarin | 1 | 2016 | 67 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2016 | 122 | 0.120 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2015 | 2 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 216 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2006 | 108 | 0.110 |
Why?
|
| Cytokines | 1 | 2019 | 678 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2006 | 105 | 0.110 |
Why?
|
| Prognosis | 2 | 2015 | 861 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 652 | 0.110 |
Why?
|
| Epidermal Growth Factor | 2 | 2016 | 70 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2018 | 1604 | 0.100 |
Why?
|
| Receptors, Cell Surface | 2 | 2005 | 146 | 0.100 |
Why?
|
| Quinazolines | 1 | 2013 | 38 | 0.100 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 934 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 2 | 2011 | 99 | 0.090 |
Why?
|
| Male | 6 | 2018 | 23409 | 0.090 |
Why?
|
| Progestins | 1 | 2011 | 11 | 0.090 |
Why?
|
| Umbilical Cord | 1 | 2011 | 14 | 0.090 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 49 | 0.090 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 17 | 0.090 |
Why?
|
| Mifepristone | 1 | 2011 | 34 | 0.090 |
Why?
|
| Aged | 4 | 2018 | 8214 | 0.080 |
Why?
|
| Mice, SCID | 1 | 2011 | 158 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2011 | 127 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2011 | 125 | 0.080 |
Why?
|
| Middle Aged | 5 | 2018 | 12222 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 263 | 0.070 |
Why?
|
| Endoplasmic Reticulum | 2 | 2005 | 108 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2011 | 329 | 0.070 |
Why?
|
| Peptides | 1 | 2011 | 372 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 458 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 508 | 0.060 |
Why?
|
| Transfection | 2 | 2005 | 532 | 0.060 |
Why?
|
| Protein Transport | 1 | 2007 | 296 | 0.060 |
Why?
|
| Receptors, Growth Factor | 1 | 2006 | 11 | 0.060 |
Why?
|
| Dideoxynucleosides | 1 | 2006 | 11 | 0.060 |
Why?
|
| Androstenedione | 1 | 2005 | 19 | 0.060 |
Why?
|
| Fluorine Radioisotopes | 1 | 2006 | 12 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 173 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2006 | 69 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 114 | 0.060 |
Why?
|
| Forecasting | 1 | 2006 | 136 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 62 | 0.060 |
Why?
|
| Ovariectomy | 1 | 2005 | 127 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2005 | 181 | 0.060 |
Why?
|
| Proto-Oncogenes | 1 | 2005 | 19 | 0.060 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2005 | 60 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 77 | 0.060 |
Why?
|
| Models, Biological | 2 | 2005 | 712 | 0.060 |
Why?
|
| Receptors, Steroid | 1 | 2005 | 38 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2005 | 50 | 0.060 |
Why?
|
| Cytosol | 1 | 2005 | 97 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2005 | 165 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 186 | 0.050 |
Why?
|
| Vinblastine | 1 | 2004 | 9 | 0.050 |
Why?
|
| Cysteine | 1 | 2005 | 103 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 256 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 59 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 139 | 0.050 |
Why?
|
| Deoxycytidine | 1 | 2004 | 38 | 0.050 |
Why?
|
| RNA | 1 | 2006 | 266 | 0.050 |
Why?
|
| Mitochondria | 1 | 2007 | 523 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2006 | 302 | 0.050 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2022 | 40 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 277 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 9 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 10 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 306 | 0.050 |
Why?
|
| Lymphokines | 1 | 2002 | 18 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2005 | 386 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2006 | 1621 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 137 | 0.040 |
Why?
|
| Protein Binding | 1 | 2005 | 1082 | 0.040 |
Why?
|
| DNA Repair | 1 | 2022 | 198 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2002 | 462 | 0.040 |
Why?
|
| Mutation | 1 | 2006 | 1177 | 0.040 |
Why?
|
| Smoking | 3 | 2015 | 1024 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2004 | 1596 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2013 | 195 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2002 | 415 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 440 | 0.030 |
Why?
|
| Thiosemicarbazones | 1 | 2017 | 10 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 26 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 116 | 0.030 |
Why?
|
| Angiography | 1 | 2016 | 15 | 0.030 |
Why?
|
| Vitamin K | 1 | 2016 | 9 | 0.030 |
Why?
|
| Dyspnea | 1 | 2016 | 22 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 60 | 0.030 |
Why?
|
| Chest Pain | 1 | 2016 | 49 | 0.030 |
Why?
|
| beta Catenin | 1 | 2017 | 78 | 0.030 |
Why?
|
| Proline-Rich Protein Domains | 1 | 2016 | 7 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2016 | 43 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2016 | 31 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 260 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 355 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 159 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 1028 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 64 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 883 | 0.020 |
Why?
|
| Adult | 3 | 2016 | 13872 | 0.020 |
Why?
|
| Beverages | 1 | 2006 | 66 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2006 | 84 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 93 | 0.010 |
Why?
|
| S-Nitrosothiols | 1 | 2005 | 4 | 0.010 |
Why?
|
| COS Cells | 1 | 2005 | 68 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2005 | 91 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2005 | 148 | 0.010 |
Why?
|
| Epirubicin | 1 | 2004 | 1 | 0.010 |
Why?
|
| Floxuridine | 1 | 2004 | 3 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2004 | 32 | 0.010 |
Why?
|
| Carboplatin | 1 | 2004 | 20 | 0.010 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2004 | 34 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 92 | 0.010 |
Why?
|
| Taxoids | 1 | 2004 | 50 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 64 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2004 | 97 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 518 | 0.010 |
Why?
|
| Nerve Tissue | 1 | 2003 | 7 | 0.010 |
Why?
|
| Binding Sites | 1 | 2005 | 671 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 1067 | 0.010 |
Why?
|
| Ions | 1 | 2003 | 71 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 2003 | 37 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 257 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 592 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 536 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2006 | 1600 | 0.010 |
Why?
|
| Cell Line | 1 | 2005 | 1410 | 0.010 |
Why?
|